...of the Biogen Inc. (NASDAQ:BIIB) mAb than they had a year ago.Executive Editor Jeff Cranmer is watching Vertex Pharmaceuticals Inc....

...growing competition against its sickle cell program, among them an early stage CRISPR therapy from Vertex Pharmaceuticals Inc....

...commercialization. Ribometrix also has an ongoing partnership Vertex Pharmaceuticals Inc....

...small molecule inhibitors of two epigenetic cancer targets in the helicase and histone acetyltransferase (HAT) families. Vertex...
...CD276)GD2 - Ganglioside GD2GPR35 – G protein-coupled receptor 35IL-15 – Interleukin-15PDE-4 - Phosphodiesterase-4 Virginia Li Skyhawk Therapeutics Inc. Vertex Pharmaceuticals Inc. Prevail...

...liver diseases, hired Tara Kieffer as SVP, new product strategy and development. She joins from Vertex Pharmaceuticals Inc....

...Assistant Editor Vertex, CRISPR update long-term data for edited cell therapyCRISPR Therapeutics AG (NASDAQ:CRSP) and Vertex Pharmaceuticals Inc....
...I Sandi Wong AFM13 AUTO3 PF-06863135 KO-539 Ciltacabtagene autoleucel (JNJ-68284528, JNJ-4528, LCAR-B38M) CTX001 Affimed N.V. Autolus Ltd. Pfizer Inc. Legend Biotech Corp. Johnson & Johnson American Society of Hematology Vertex Pharmaceuticals Inc. CRISPR...

...come out?[00:04:23] Lauren Martz: The CRISPR and Vertex...

...Phase II testing. Merck obtained molecules targeting ATR and DNA-PK in a 2017 deal with Vertex Pharmaceuticals Inc....

...therapy, NTLA-2001 from Intellia Therapeutics Inc. (NASDAQ:NTLA) and Vertex Pharmaceuticals Inc....

...of Tavistock Group, Janus Henderson, Samsara Biocapital and Vivo Capital and existing investors Aisling Capital, Vertex...